Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090461 · ClinicalTrials.gov registry record
Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
A clinical trial, sponsored by Currax Pharmaceuticals.
- Completed
- Registry status
- 31,889
- Enrollment target
NCT06090461: Completed study, sponsored by Currax Pharmaceuticals.
NCT06090461 is a clinical trial that has completed, run by Currax Pharmaceuticals. The registered enrollment target is 31,889 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06090461 has completed, sponsored by Currax Pharmaceuticals.
- COMPLETED
- Registry status
- 31,889 participants
- Enrollment target
Study Summary
The fixed-dose combination of naltrexone 8mg and bupropion 90mg extended-release oral tablet is marketed under the trade name CONTRAVE® in the U.S. In this protocol, the investigators propose to generate real-world evidence (RWE) from electronic health records (EHR) and linked claims data to assess the cardiovascular safety of CONTRAVE® and all combined use of naltrexone and bupropion (NB) in usual clinical practice.
Primary Outcome
The primary study endpoint is MACE, defined as the composite of: * Medically attended non-fatal acute myocardial infarction (AMI); * Medically attended non-fatal stroke; * Cardiovascular death.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31,889 participants |
| Start Date | 2014-09 |
| Est. Completion | 2022-12 |
What the finished NCT06090461 record still lists
NCT06090461 is an observational study that tracks outcomes without assigning an intervention. Its 31,889 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT06090461 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06090461 about?
NCT06090461 is a clinical study titled "Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)". The fixed-dose combination of naltrexone 8mg and bupropion 90mg extended-release oral tablet is marketed under the trade name CONTRAVE® in the U.S. In this protocol, the investigators propose to generate real-world evidence (RWE) from electronic health records (EHR) and linked claims data to assess ...
What is the current status of trial NCT06090461?
This trial is currently completed. The enrollment target is 31,889 participants. The study started on 2014-09. Estimated completion is 2022-12.
Who is sponsoring clinical trial NCT06090461?
This trial is sponsored by Currax Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07282665 · 32,000 participants · Phase 3
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
- NCT04477928 · 33,000 participants
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
- NCT06145724 · 33,183 participants · NA
EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1)
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia